Trials / Completed
CompletedNCT03960268
Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab
A Pilot Study of Safety and Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Rockefeller University · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
Phase 0 Study of Brodalumab in patients with moderate to severe Hidradenitis Suppurativa to identify biomarkers of disease activity and clinical response.
Detailed description
Phase 0, Open Label study of Brodalumab in patients with moderate to severe Hidradenitis Suppurativa. Consisting of n=10 patients receiving 210mg subcutaneously every 2 weeks for 24 weeks. Patients will be followed for a period of 36 weeks (12 weeks after last dose of Brodalumab) to assess for safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brodalumab | interleukin 17 receptor A antagonist |
Timeline
- Start date
- 2019-05-28
- Primary completion
- 2020-06-01
- Completion
- 2020-06-01
- First posted
- 2019-05-23
- Last updated
- 2020-06-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03960268. Inclusion in this directory is not an endorsement.